Skip to content
Altay Therapeutics logo

Altay Therapeutics

Altay Therapeutics is a YC Winter 2020 (W20) company. Based in San Carlos, CA, USA; South San Francisco, CA, USA. Team of 6.

  • AI-powered Drug Discovery
  • Biotech
  • Therapeutics
  • Drug discovery

About Altay Therapeutics

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

Altay Therapeutics develops oral small molecule inhibitors targeting transcription factors, a class of proteins long considered undruggable, for serious diseases with few treatment options. Its lead program, DX5057, is a DUX4 inhibitor for facioscapulohumeral muscular dystrophy (FSHD), and its STAT3 inhibitor targets cancer and chronic inflammatory diseases. The work replaces the absence of any approved oral transcription factor therapy in these indications.

Go-to-market

Altay's primary customers are patients and clinicians in rare and underserved disease areas; the company advances candidates through its own pipeline toward IND-enabling studies and Phase 1/2a trials rather than through a partnered or out-licensed model at this stage.

From the Y Combinator listing

How Altay Therapeutics describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

Altay develops disease-modifying therapies targeting transcription…

Altay develops small molecule drugs to treat chronic liver diseases like liver fibrosis and liver cancer. Our co-founder Dr. Osman Ozes, led the first drug development program for Esbriet (Pirfenidone), resulting in the first FDA approved therapy for lung fibrosis. Esbriet is now a $1 billion/year drug and has already made over $6 billion in revenue. With a team that has over 70+ years of small molecule drug development experience, we intend to do the same with chronic liver diseases, which affects over 20 million Americans and represents a market size of over $30 billion. We know we are well positioned for success because we have shown excellent pre-clinical mouse data in several liver fibrosis models using our novel small molecule. We demonstrate a reduction in fibrosis with our drug, but more significantly, we show a reversal in fibrotic tissue back to normal tissue. With our current developmental strategy, we hope to have a clinic-ready compound by the end of 2021 and be in phase I clinical trials by mid of 2022.

Facts

Industry
Healthcare / Healthcare -> Therapeutics
Location
San Carlos, CA, USA; South San Francisco, CA, USA
Team size
6
Status
Active
Stage
Early

Founders (2)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works